Literature DB >> 9715817

Basic mechanisms of disease progression in the failing heart: the role of excessive adrenergic drive.

D L Mann1.   

Abstract

This review examines experimental evidence that suggests that excessive adrenergic stimulation of the heart may actually contribute to the untoward natural history of congestive heart failure. The basic mechanisms for catecholamine-mediated cardiac toxicity are discussed, as well as relatively new evidence that catecholamine-mediated toxicity is the result of beta-adrenoceptor-mediated cyclic adenosine monophosphate-dependent calcium overload of the cardiac myocyte. The studies reviewed herein provide a plausible biological rationale for the use of beta-adrenergic blocking agents in patients with heart failure.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9715817     DOI: 10.1016/s0033-0620(98)80025-x

Source DB:  PubMed          Journal:  Prog Cardiovasc Dis        ISSN: 0033-0620            Impact factor:   8.194


  11 in total

1.  CXCR4 modulates contractility in adult cardiac myocytes.

Authors:  Robert T Pyo; Jinliang Sui; Ashwini Dhume; Julieta Palomeque; Burns C Blaxall; George Diaz; James Tunstead; Diomedes E Logothetis; Roger J Hajjar; Alison D Schecter
Journal:  J Mol Cell Cardiol       Date:  2006-09-28       Impact factor: 5.000

2.  Multiphasic Regulation of Systemic and Peripheral Organ Metabolic Responses to Cardiac Hypertrophy.

Authors:  Chong Wee Liew; Shanshan Xu; Xuerong Wang; Maximilian McCann; Hyerim Whang Kong; Andrew C Carley; Jingbo Pang; Giamila Fantuzzi; J Michael O'Donnell; E Douglas Lewandowski
Journal:  Circ Heart Fail       Date:  2017-04       Impact factor: 8.790

Review 3.  Risk of heart failure progression in patients with reduced ejection fraction: mechanisms and therapeutic options.

Authors:  Edoardo Gronda; Emilio Vanoli; Stefania Sacchi; Guido Grassi; Giuseppe Ambrosio; Claudio Napoli
Journal:  Heart Fail Rev       Date:  2020-03       Impact factor: 4.214

Review 4.  Electrical modulation of cardiac contractility: clinical aspects in congestive heart failure.

Authors:  C Pappone; G Vicedomini; A Salvati; C Meloni; W Haddad; R Aviv; Y Mika; N Darvish; Y Kimchy; I Shemer; Y Snir; D Pruchi; S A Ben-Haim; I Kronzon
Journal:  Heart Fail Rev       Date:  2001-01       Impact factor: 4.214

5.  Heterogeneous ventricular sympathetic innervation, altered beta-adrenergic receptor expression, and rhythm instability in mice lacking the p75 neurotrophin receptor.

Authors:  Christina U Lorentz; Eric N Alston; Todd Belcik; Jonathan R Lindner; George D Giraud; Beth A Habecker
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-02-26       Impact factor: 4.733

6.  Neurohormonal Therapy for Congestive Heart Failure.

Authors:  Allison M Pritchett; Douglas L Mann
Journal:  Curr Treat Options Cardiovasc Med       Date:  2004-12

7.  A Retinoic Acid β2-Receptor Agonist Exerts Cardioprotective Effects.

Authors:  Alice Marino; Takuya Sakamoto; Xiao-Han Tang; Lorraine J Gudas; Roberto Levi
Journal:  J Pharmacol Exp Ther       Date:  2018-06-15       Impact factor: 4.030

Review 8.  Hypertension and concomitant diseases: a guide for evidence-based therapy.

Authors:  Tamrat M Retta; Otelio S Randall
Journal:  J Natl Med Assoc       Date:  2004-04       Impact factor: 1.798

Review 9.  MMP induction and inhibition in myocardial infarction.

Authors:  Merry L Lindsey
Journal:  Heart Fail Rev       Date:  2004-01       Impact factor: 4.214

Review 10.  Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology.

Authors:  Stephane Heymans; Emilio Hirsch; Stefan D Anker; Pal Aukrust; Jean-Luc Balligand; Jan W Cohen-Tervaert; Helmut Drexler; Gerasimos Filippatos; Stephan B Felix; Lars Gullestad; Denise Hilfiker-Kleiner; Stefan Janssens; Roberto Latini; Gitte Neubauer; Walter J Paulus; Burkert Pieske; Piotr Ponikowski; Blanche Schroen; Heinz-Peter Schultheiss; Carsten Tschöpe; Marc Van Bilsen; Faiez Zannad; John McMurray; Ajay M Shah
Journal:  Eur J Heart Fail       Date:  2009-02       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.